Obscure Gastrointestinal Bleeding Clinical Trial
— PrepRICEOfficial title:
Preparation Regimens to Improve Capsule Endoscopy Visualization and Diagnostic Yield: a Randomized Trial
NCT number | NCT05140057 |
Other study ID # | 0001 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | December 1, 2021 |
Est. completion date | October 31, 2023 |
Verified date | November 2021 |
Source | Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Small bowel capsule endoscopy (SBCE) has become an important tool in clinical practice since its introduction in 2000. This non-invasive method allows the visualization of small bowel mucosa, being essential in the management of many conditions, such as suspected small bowel bleeding, inflammatory bowel diseases and intestinal polyposis syndromes. Despite recommendations concerning SBCE in different pathologies, there are still some technical concerns to be addressed. The optimal preparation for SBCE has been one of these controversial issues. Currently, the European Society of Gastrointestinal Endoscopy (ESGE) recommends that patients ingest a purgative agent (2L of polyethylene glycol, PEG) and antifoaming agents for SBCE, because it was associated with a better visualization. However, it remains unclear which is the optimal timing for purgative use. Furthermore, the use of a booster agent after capsule ingestion is already performed in colon capsule endoscopy, but less is known about its application in SBCE. Also, it remains to be clarified whether a better visualization results in higher diagnostic yield and impacts patients' outcomes. Therefore, the global aim of this prospective, randomized, multi-centric study is to determine the optimal timing and preparation for small-bowel capsule endoscopy (regardless of the equipment used), comparing four groups of different preparation protocols: - Protocol 1) 1L of Moviprep® solution the night before the procedure - Protocol 2) 1L of Moviprep® solution up to 2h before the procedure - Protocol 3) 0.5L of Moviprep® solution up to 2h before the procedure plus 0.5L of Moviprep® solution after the capsule had reached the duodenum (assessed with real-time viewer) - Protocol 4) 1L of Moviprep® solution after the capsule had reached the duodenum (assessed using real-time viewer)
Status | Recruiting |
Enrollment | 210 |
Est. completion date | October 31, 2023 |
Est. primary completion date | October 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Be 18 years old or older - Present OGIB (either occult or overt) - Agree with study's procedures and have signed the informed consent for the study and SBCE, prior to SBCE procedure Exclusion Criteria: - Patients performing capsule endoscopy in urgent setting for overt obscure GI bleeding - Inpatients or bedridden - History of surgery of the esophagus, stomach, small bowel, or colon - History of abdominal or pelvic radiation therapy - Suspected or confirmed stenosis or occlusion - Suspected or confirmed bowel perforation - Severe comorbidities, as defined by grade 3 "severe decompensation" in the Adult Comorbidity Evaluation-27 index (ACE-27) - Pregnant women - Patients using narcotics or prokinetics in the week before the SBCE |
Country | Name | City | State |
---|---|---|---|
Portugal | Department of Gastroenterology, Centro Hospitalar Vila Nova de Gaia/Espinho | Vila Nova De Gaia |
Lead Sponsor | Collaborator |
---|---|
Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E. |
Portugal,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diagnostic yield | Proportion of SBCE with positive findings. findings will be classified based on the Saurin classification; the investigators will consider a positive SBCE when lesions classified as P2 or active bleeding are detected (Saurin classification, Table 2), the remaining will be classified as negative | During the procedure | |
Primary | Adequate cleansing rate | A cutoff value of quantitative index = 8 points | During the procedure | |
Secondary | Proportion of SBCE with vascular lesions | Vascular lesions identified in each tertile | During the procedure | |
Secondary | Proportion of SBCE with active bleeding | Active bleeding in each tertile | During the procedure | |
Secondary | Diagnostic yield per tertile | Positive findings in each tertile | During the procedure | |
Secondary | Transit times | Time of entry in the stomach, duodenum and cecum | During the procedure | |
Secondary | Symptoms experienced during SBCE procedure | Nausea, vomit, bloating, abdominal pain | During the procedure | |
Secondary | Overall patients' satisfaction with the cleansing regimen | rated on a 5-point scale: 1 - very easy, 2 - easy, 3 - intermediate, 4 - difficult, 5 - very difficult | During the procedure | |
Secondary | Small bowel cleansing | Mean quantitative index of the distal third of small bowel | During the procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT00593021 -
Diagnostic Evaluation of Obscure Gastrointestinal Bleeding
|
N/A | |
Completed |
NCT00964496 -
Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation
|
Phase 2 | |
Completed |
NCT01625585 -
Single Balloon Enterosocpy Obscure Gastrointestinal Bleeding Bleed
|
N/A | |
Completed |
NCT00203619 -
Capsule Endoscopy in Obscure GI Bleeding
|
N/A | |
Active, not recruiting |
NCT05731388 -
Assessing Depth of Small Bowel Insertion at Push Enteroscopy by Using Capsule Endoscopy
|
||
Terminated |
NCT02315404 -
Cap Assisted Balloon Enteroscopy Versus Conventional Balloon Enteroscopy In The Evaluation Of Obscure Gastrointestinal Bleeding: A Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT04646083 -
Depth of Maximal Ileal Insertion During Retrograde Enteroscopy With TTS Balloon
|
||
Completed |
NCT04821349 -
Role of AI in CE for the Identification of SB Lesions in Patients With Small Intestinal Bleeding.
|
N/A |